NOIDA, India, Nov. 17 /PRNewswire/ -- Jubilant Organosys Ltd. announced today that its subsidiary Clinsys Clinical Research, Inc.(R), New Jersey, a global contract research organization (CRO), has acquired TrialStat ClinicalAnalytics(R) from TrialStat(R) for a purchase consideration of CAD 750,000.
TrialStat ClinicalAnalytics (TrialStat CA) is a Web-based electronic data capture (EDC) solution currently used by a wide range of pharmaceutical and CRO customers worldwide. TrialStat CA is the industry's first EDC platform to allow all aspects of a study to be configured, deployed and managed through a browser interface, enabling customers to start their studies quickly and cost-effectively.
Clinsys extensive global resources will enable TrialStat to continue its proven record of growth, customer service and product innovation. This agreement will give TrialStat's existing CRO and biopharmaceutical customer base a broader scope of services.
"The Company had identified TrialStat ClinicalAnalytics as one of the most innovative EDC solutions on the market and was determined to include it in its offerings to its customers globally," said David E. Williams, Chief Executive Officer of Clinsys.
Commenting on the acquisition, Mr. Shyam S Bhartia, Chairman & Managing Director and Mr. Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Organosys Ltd., said, "The addition of the TrialStat CA and its proven EDC offering will allow Clinsys to continue to expand its integrated solutions for pharmaceutical, biotechnology and medical device organizations. This acquisition is an excellent fit and addresses the industry's continuously evolving requirements in EDC."
About Jubilant Organosys
Jubilant Organosys Ltd. is an integrated pharmaceutical industry player, the largest custom research and manufacturing services (CRAMS) and drug discovery and development services companies out of India. The Company has a presence across the pharmaceutical value chain for products and services that include exclusive synthesis arrangements, active pharmaceutical ingredients, contract manufacturing of sterile injectables (liquids and lyophilized) products, non-steriles (ointments, creams and liquid) radiopharmaceuticals, Integrated drug discovery solutions, medicinal chemistry services, clinical research services, dosage forms and Health Care.
For more information visit: www.jubl.com
About Clinsys Clinical Research, Inc.
Clinsys Clinical Research, Inc., is a therapeutically focused global contract research organization that provides pharmaceutical, biotechnology and medical device companies with a full range of Phase I-IV clinical research services, including clinical development, study start-up, clinical operations, biostatistics, data management, quality assurance, regulatory affairs, pharmacovigilance, medical writing, clinical pharmacology & pathology, and functional outsourcing services.
Clinsys is a Jubilant Organosys company headquartered in Bedminster, New Jersey, with operations in Raleigh, North Carolina; Philadelphia, Pennsylvania; and Dusseldorf, Germany. Clinsys Clinical Research, Ltd., with offices in Noida and Bangalore, India. Clinsys employs 400 people globally.
For more information, visit www.clinsys.com.
For further information please contact:
Disclaimer:
Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Organosys may, from time to time, make additional written and oral forward looking statements, including statements contained in the Company's filings with the regulatory bodies and its reports to shareholders. The Company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.
CONTACT: India, Media, Seema Ahuja, Jubilant Organosys Limited,
+91-120-4361062, Mobile, +91-9810631779, seema_ahuja@jubl.com, or
Investors, Deepak Malik, Jubilant Organosys Limited, +91-120 4361114, Fax:
+91-120-2516629, deepak_malik@jubl.com; or Siddharth Rangnekar, Citigate
Dewe Rogerson, +91-22 4007 5005, Fax: +91-22-2284 4561,
siddharth@cdr-india.com; or USA-Canada, Mitchell Winfree, Vice President,
Global Business Development and Marketing, Clinsys Clinical Research, Inc.,
+1-919-889-2992, mwinfree@clinsys.com
Web site: http://www.clinsys.com/
http://www.jubl.com/
